Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2013
05/01/2013CN101282721B Composition for relieving subjective symptoms of fatigue
05/01/2013CN101277705B Agent for amelioration of insulin resistance
05/01/2013CN101134036B Preparations containing rebeprazole and sodium bicarbonate and method for preparing the same
04/2013
04/30/2013USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
04/30/2013US8431806 Liposomal formulations of anthracycline agents and cytidine analogs
04/30/2013US8431768 Targeted and regional cellular ablation in zebrafish
04/30/2013US8431731 Glyceryl and glycol acid compounds
04/30/2013US8431715 Thiazole compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof
04/30/2013US8431713 2-aminopyridine derivatives as glucokinase activators
04/30/2013US8431712 Methods for the synthesis of pyridoxamine
04/30/2013US8431708 Fluorescent carbazole compounds for cancer diagnosis
04/30/2013US8431706 1,2,3,4-tetrahydroqinoline derivative useful for the treatment of diabetes
04/30/2013US8431703 Pyrrolopyridine compounds and their use in treating disease
04/30/2013US8431702 Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
04/30/2013US8431695 Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
04/30/2013US8431617 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
04/30/2013US8431616 Method for producing a disinfecting agent
04/30/2013US8431615 Dose forms
04/30/2013US8431614 Loxoprofen derivative and pharmaceutical preparation containing the same
04/30/2013US8431613 Memory fixation accelerator
04/30/2013US8431611 Artemisinin derivatives
04/30/2013US8431610 Alkanoylamino benzamide aniline HDAC inhibitor compounds
04/30/2013US8431609 Process for preparation of pyrazole derivatives
04/30/2013US8431608 Heterocycles as potassium channel modulators
04/30/2013US8431607 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
04/30/2013US8431606 Medicament for treating schizophrenia comprising cilostazol
04/30/2013US8431605 Modulators of ATP-binding cassette transporters
04/30/2013US8431604 Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
04/30/2013US8431603 3-phenylpyrazolo[5,1-b]thiazole compounds
04/30/2013US8431602 Beta-amino acid derivatives for treatment of diabetes
04/30/2013US8431601 Topical compositions comprising telmesteine for treating dermatological disorders
04/30/2013US8431599 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
04/30/2013US8431598 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
04/30/2013US8431597 Benzimidazole derivatives
04/30/2013US8431596 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
04/30/2013US8431595 Furanopyridine cannabinoid compounds and related methods of use
04/30/2013US8431594 Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
04/30/2013US8431593 Heteroaryl amide derivatives
04/30/2013US8431592 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors
04/30/2013US8431591 R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
04/30/2013US8431590 Spiroindolines as modulators of chemokine receptors
04/30/2013US8431589 2,4-diaminopyrimidine derivatives
04/30/2013US8431588 Cyclopropyl polymerase inhibitors
04/30/2013US8431587 Method for the treatment of cancer
04/30/2013US8431586 Quinazoline derivatives and pharmaceutical compositions thereof
04/30/2013US8431585 Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
04/30/2013US8431584 Heterobicyclic carboxamides as inhibitors for kinases
04/30/2013US8431582 Inhibitors of fatty acid uptake and methods of use
04/30/2013US8431581 Imidazopyrimidines and uses thereof
04/30/2013US8431579 Capped pyrazinoylguanidine sodium channel blockers
04/30/2013US8431578 Organic compounds
04/30/2013US8431577 Crystalline form of eszopiclone, composition, preparation and uses thereof
04/30/2013US8431576 Heterocyclic compounds for the treatment of neurological and psychological disorders
04/30/2013US8431575 Phenyl-heteroaryl derivatives and methods of use thereof
04/30/2013US8431574 Heterocyclic inhibitors of MEK and methods of use thereof
04/30/2013US8431573 Cyanopyrimidinones
04/30/2013US8431572 2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumours
04/30/2013US8431571 Compounds for enzyme inhibition
04/30/2013US8431570 Methods of utilizing arylpiperazine derivatives
04/30/2013US8431569 Inhibitors of janus kinases
04/30/2013US8431568 Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
04/30/2013US8431567 Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands
04/30/2013US8431566 Cyclopamine lactam analogs and methods of use thereof
04/30/2013US8431565 Substituted imidazoheterocycles
04/30/2013US8431564 Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
04/30/2013US8431563 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes
04/30/2013US8431562 Crystalline sodium salt of cephalosporin antibiotic
04/30/2013US8431561 Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
04/30/2013US8431560 Methods of treating hypertriglyceridemia
04/30/2013US8431559 Treatment of hot flashes
04/30/2013US8431558 Compositions and methods for modification of biomolecules
04/30/2013US8431557 Treatment of menopause-associated symptoms
04/30/2013US8431556 C-21-keto lupane derivatives preparation and use thereof
04/30/2013US8431555 Topical steroidal formulations
04/30/2013US8431554 Compound showing anti-inflammatory activity and antiviral activity, pharmaceutical compositions comprising the same, a process for obtaining the same and use of the same in the treatment of epidemic keratoconjunctivites and herpetic stromal keratis
04/30/2013US8431553 Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
04/30/2013US8431552 first agent is an oxidative phosphorylation inhibitor (metformin) or an ionophore or an adenosine 5'-monophosphate-activated Protein kinase (AMPK) activator; second agent is antiinflammatory agent; and an third agent that possesses serotonin activity
04/30/2013US8431551 Nutritional composition made using isolated organic matter
04/30/2013US8431549 Methods and compositions for administration of iron
04/30/2013US8431548 Method for placental exfoliation using oxo-arachidonic acid or the like
04/30/2013US8431546 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
04/30/2013US8431541 Alpha-amylase inhibitors: the montbretins and uses thereof
04/30/2013US8431527 Methods for alleviating deleterious effects of 3-deoxyglucosone
04/30/2013US8431522 Methods of inhibiting tumor cell proliferation
04/30/2013US8431380 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
04/30/2013US8431161 Microparticle and pharmaceutical composition thereof
04/30/2013US8431159 Solid pharmaceutical dispersions with enhanced bioavailability
04/30/2013US8431156 Pharmaceutical composition
04/30/2013US8431155 Bromocriptine formulations
04/30/2013US8431154 Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
04/30/2013US8431153 Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
04/30/2013US8431152 Transdermally absorbable preparation
04/30/2013US8431143 Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation
04/30/2013US8431141 Alloplastic injectable dermal filler and methods of use thereof
04/30/2013US8431140 Topical compositions
04/30/2013US8431124 Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
04/30/2013US8431119 Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
04/30/2013US8431114 Polysaccharide-based polymer tissue adhesive for medical use
04/30/2013US8431113 Polymer conjugates
04/30/2013CA2737851C Controlled release preparation